» Articles » PMID: 11312400

Degranulation Patterns of Eosinophil Granulocytes As Determinants of Eosinophil Driven Disease

Overview
Journal Thorax
Date 2001 Apr 20
PMID 11312400
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Degranulation of eosinophils in target tissues is considered a key pathogenic event in major chronic eosinophilic diseases. However, because of a lack of appropriate methods, little is known about degranulation of eosinophils in common eosinophilic diseases.

Methods: Using transmission electron microscopic (TEM) analysis, a novel approach has been devised and validated to quantify eosinophil degranulation in human tissues (assessed in individual cells as percentage granules with structural signs of protein release). Biopsy specimens from patients with inflammatory bowel disease, allergic rhinitis, asthma, and nasal polyposis were evaluated.

Results: All conditions displayed a similar degree of local tissue eosinophilia, with no differences being observed in eosinophil numbers in the airway mucosa of patients with airway diseases and the colonic mucosa of those with inflammatory bowel disease (IBD). In contrast, marked differences in the mean (SE) extent of eosinophil degranulation were observed between the patient groups; IBD 9.3 (1.4)% altered granules, artificial and natural allergen challenge induced allergic rhinitis 67.8 (6.8)% and 86.6 (3.0)%, respectively, asthma 18.1 (2)%, and nasal polyposis 46.6 (7.6)%.

Conclusions: This study provides the first quantitative data which show that different eosinophilic conditions, despite having similar numbers of tissue eosinophils, may exhibit markedly different degranulation patterns. The present assessment of piecemeal degranulation would thus make it possible to delineate the conditions under which eosinophils are likely to contribute to disease processes. This novel type of analysis may also guide and validate anti-eosinophilic treatment options.

Citing Articles

Eosinophil extracellular traps in respiratory ailment: Pathogenic mechanisms and clinical translation.

Wu S, Cai B, Wang T, Cao Z, Peng H, Liu H World J Otorhinolaryngol Head Neck Surg. 2024; 10(3):213-224.

PMID: 39233861 PMC: 11369806. DOI: 10.1002/wjo2.138.


Eosinophils as drivers of bacterial immunomodulation and persistence.

Parrish K, Gestal M Infect Immun. 2024; 92(9):e0017524.

PMID: 39007622 PMC: 11385729. DOI: 10.1128/iai.00175-24.


Eosinophils promote pulmonary matrix destruction and emphysema via Cathepsin L.

Xu X, Yu T, Dong L, Glauben R, Wu S, Huang R Signal Transduct Target Ther. 2023; 8(1):390.

PMID: 37816708 PMC: 10564720. DOI: 10.1038/s41392-023-01634-x.


Eosinophil extracellular traps in asthma: implications for pathogenesis and therapy.

Shen K, Zhang M, Zhao R, Li Y, Li C, Hou X Respir Res. 2023; 24(1):231.

PMID: 37752512 PMC: 10523707. DOI: 10.1186/s12931-023-02504-4.


Galectin-10 as a Potential Biomarker for Eosinophilic Diseases.

Tomizawa H, Yamada Y, Arima M, Miyabe Y, Fukuchi M, Hikichi H Biomolecules. 2022; 12(10).

PMID: 36291593 PMC: 9599181. DOI: 10.3390/biom12101385.


References
1.
Kita H, Weiler D, ABU-GHAZALEH R, Sanderson C, Gleich G . Release of granule proteins from eosinophils cultured with IL-5. J Immunol. 1992; 149(2):629-35. View

2.
Kroegel C, Dewar A, Yukawa T, Venge P, Barnes P, Chung K . Ultrastructural characterization of platelet-activating factor-stimulated human eosinophils from patients with asthma. Clin Sci (Lond). 1993; 84(4):391-9. DOI: 10.1042/cs0840391. View

3.
Jahnsen F, Brandtzaeg P, Halstensen T . Monoclonal antibody EG2 does not provide reliable immunohistochemical discrimination between resting and activated eosinophils. J Immunol Methods. 1994; 175(1):23-36. DOI: 10.1016/0022-1759(94)90328-x. View

4.
Persson C, Erjefalt J . Eosinophil lysis and free granules: an in vivo paradigm for cell activation and drug development. Trends Pharmacol Sci. 1997; 18(4):117-23. DOI: 10.1016/s0165-6147(97)01042-0. View

5.
Cheng J, Ott N, Peterson E, George T, Hukee M, Gleich G . Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration. J Allergy Clin Immunol. 1997; 99(5):683-92. DOI: 10.1016/s0091-6749(97)70031-9. View